학술논문
Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study.
Document Type
Article
Author
Source
Subject
*DISEASE relapse
*IODINE radioisotopes
*BIOMARKERS
*COMPARATIVE studies
*CONFIDENCE intervals
*GLOBULINS
*LONGITUDINAL method
*NECK surgery
*STATISTICS
*THYROID gland tumors
*RELATIVE medical risk
*RETROSPECTIVE studies
*PROGNOSIS
*THERAPEUTICS
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0022-2151
Abstract
Background:Serum thyroglobulin is used as a surrogate marker for well-differentiated thyroid carcinoma recurrence. This study investigates whether thyroglobulin measured at the time of ablative radioactive iodine therapy predicts disease-free survival.Methods:A retrospective review was conducted of patients with well-differentiated thyroid carcinoma presenting from 1989 to 2010 at the Royal Prince Alfred Hospital, New South Wales, Australia. Disease-free survival of patients with a significantly elevated stimulated thyroglobulin level (27.5 µg/l or higher) at the time of ablative radioactive iodine therapy was compared to that of patients without a significantly elevated thyroglobulin level using univariate analysis.Results:Patients with a thyroglobulin level of 27.5 µg/l or higher had an increased relative risk of disease recurrence of 4.50 (95 per cent confidence interval = 1.35–15.04). If lateral neck dissection was required at the time of surgery, patients also had an increased relative risk of macroscopic disease recurrence of 4.94 (95 per cent confidence interval = 1.47–16.55).Conclusion:An elevated thyroglobulin level of 27.5 µg/l or higher at the time of ablative radioactive iodine therapy is a prognostic indicator for macroscopic disease recurrence in well-differentiated thyroid carcinoma. [ABSTRACT FROM AUTHOR]